Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Influenza A virus hemagglutinin (HA) sialic acid receptor-binding site (RBS) is a critical functional domain located on the distal globular head of the HA surface glycoprotein [4, 12]. Its primary biological role is to mediate the initial attachment of the virus to host cells by binding to terminal sialic acid residues on cell-surface glycoproteins and glycolipids, a process that initiates the viral entry cycle [7, 17]. The RBS is composed of several conserved structural elements, including the 130-loop, 150-loop, 190-helix, and 220-loop, which coordinate to define the site's affinity and specificity for different sialic acid linkages [4, 12]. This specificity is a key determinant of host tropism, distinguishing between avian-like (alpha-2,3) and human-like (alpha-2,6) receptors, and is thus a major factor in pandemic potential [13, 23]. In the context of disease, the RBS is the primary target for the host's neutralizing antibody response; however, the virus frequently undergoes antigenic drift through mutations in and around the RBS to evade this immunity [12, 18]. Therapeutically, the RBS is a major focus for the development of universal vaccines and entry inhibitors [1, 10]. While most seasonal vaccines elicit strain-specific antibodies, research into broadly neutralizing antibodies (bnAbs) like C05 and CH65, as well as small-molecule mimics and peptides like the EB peptide, aims to target the conserved core of the RBS to provide protection against a wide range of influenza subtypes [6, 10, 20]. Challenges in targeting this site include glycan shielding and the need to maintain a functional balance between HA binding and neuraminidase cleavage for efficient viral fitness [5, 11, 19].
Inhibition of viral attachment to host cell sialic acid receptors, thereby preventing viral entry and subsequent replication.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A virus hemagglutinin (HA) sialic acid receptor-binding site (HA RBS).